BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 38340290)

  • 1. Helicobacter pylori Eradication Treatment in Older Patients.
    Jonaitis P; Kupcinskas J; Gisbert JP; Jonaitis L
    Drugs Aging; 2024 Feb; 41(2):141-151. PubMed ID: 38340290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimum duration of regimens for Helicobacter pylori eradication.
    Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of high-dose dual therapy with bismuth-containing quadruple therapy in Helicobacter pylori-infected treatment-naive patients: An open-label, multicenter, randomized controlled trial.
    Guan JL; Hu YL; An P; He Q; Long H; Zhou L; Chen ZF; Xiong JG; Wu SS; Ding XW; Luo HS; Li PY
    Pharmacotherapy; 2022 Mar; 42(3):224-232. PubMed ID: 35075679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice.
    Nyssen OP; Perez-Aisa A; Castro-Fernandez M; Pellicano R; Huguet JM; Rodrigo L; Ortuñ J; O ; Gomez-Rodriguez BJ; Pinto RM; Areia M; Perona M; Nuñez O; Romano M; Gravina AG; Pozzati L; Fernandez-Bermejo M; Venerito M; Malfertheiner P; Fernanadez-Salazar L; Gasbarrini A; Vaira D; Puig I; Megraud F; O'Morain C; Gisbert JP;
    United European Gastroenterol J; 2021 Feb; 9(1):38-46. PubMed ID: 33176617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
    Fu W; Song Z; Zhou L; Xue Y; Ding Y; Suo B; Tian X; Wang L
    Dig Dis Sci; 2017 Jun; 62(6):1580-1589. PubMed ID: 28391418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High Effective of 14-Day High-Dose PPI- Bismuth-Containing Quadruple Therapy with Probiotics Supplement for Helicobacter Pylori Eradication: A Double Blinded-Randomized Placebo-Controlled Study.
    Poonyam P; Chotivitayatarakorn P; Vilaichone RK
    Asian Pac J Cancer Prev; 2019 Sep; 20(9):2859-2864. PubMed ID: 31554388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
    Liou JM; Jiang XT; Chen CC; Luo JC; Bair MJ; Chen PY; Chou CK; Fang YJ; Chen MJ; Chen CC; Lee JY; Yang TH; Yu CC; Kuo CC; Chiu MC; Chen CY; Shun CT; Hu WH; Tsai MH; Hsu YC; Tseng CH; Chang CY; Lin JT; El-Omar EM; Wu MS;
    Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):228-241. PubMed ID: 36549320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Ten-day Sequential Therapy versus Bismuth Based Quadruple Therapy as Second Line Treatment for Helicobacter pylori Infection].
    Kim SB; Lee SH; Kim KO; Jang BI; Kim TN
    Korean J Gastroenterol; 2015 Nov; 66(5):261-7. PubMed ID: 26586348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the management of Helicobacter pylori infection between the older and younger European populations.
    Jonaitis P; Nyssen OP; Saracino IM; Fiorini G; Vaira D; Pérez-Aísa Á; Tepes B; Castro-Fernandez M; Pabón-Carrasco M; Keco-Huerga A; Voynovan I; Lucendo AJ; Lanas Á; Martínez-Domínguez SJ; Almajano EA; Rodrigo L; Vologzanina L; Brglez Jurecic N; Denkovski M; Bujanda L; Mahmudov U; Leja M; Lerang F; Babayeva G; Bordin DS; Gasbarrini A; Kupcinskas J; Gridnyev O; Rokkas T; Marcos-Pinto R; Phull PS; Smith SM; Tonkić A; Boltin D; Buzás GM; Šembera Š; Şimşek H; Matysiak-Budnik T; Milivojevic V; Marlicz W; Venerito M; Boyanova L; Doulberis M; Capelle LG; Cano-Català A; Moreira L; Mégraud F; O'Morain C; Gisbert JP; Jonaitis L;
    Sci Rep; 2023 Oct; 13(1):17235. PubMed ID: 37821503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phytomedicine-based and Quadruple Therapies in Helicobacter pylori Infection: A Comparative, Randomized Trial.
    Asif HM; Zaidi SF; Sugiyama T; Akhtar N; Usmanghani K
    Altern Ther Health Med; 2015; 21 Suppl 2():33-9. PubMed ID: 26308758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Quadruple regimens using domestically manufactured drugs in gastritis and duodenal ulcer patients for Helicobacter pylori eradication: a perspective, multicenter, randomized controlled trial].
    Gao W; Hu F; Cheng H; Wang H; Yang Y; Liang H; Zhang S; Meng F; Cui M; Wei H; Sheng J; An HJ; Jiang B; Chen Y; Li Y; Zuo X; Gong J; Zhao P; Dong L; Wang B; Jiang K; Zhang G; Li J; Zhao Y; Gao H; Yang L
    Zhonghua Yi Xue Za Zhi; 2016 Jan; 96(4):260-4. PubMed ID: 26879784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-capsule bismuth-based quadruple therapy as a rescue therapy for
    Correia C; Almeida N; Leal C; Branquinho D; Fernandes A; Gravito-Soares E; Calhau C; Bastos I; Vasconcelos H; Figueiredo P
    Scand J Gastroenterol; 2023 Mar; 58(3):227-231. PubMed ID: 36189844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection.
    Lim JH; Lee DH; Lee ST; Kim N; Park YS; Shin CM; Song IS
    World J Gastroenterol; 2015 Dec; 21(46):13124-31. PubMed ID: 26673999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
    Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
    World J Gastroenterol; 2015 Jul; 21(26):8132-9. PubMed ID: 26185386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing high-dose dual therapy with bismuth-containing quadruple therapy for the initial eradication of Helicobacter pylori infection on Hainan Island: A randomized, multicenter clinical trial.
    Liu DN; Wang QY; Li PY; Wu DH; Pan J; Chen ZY; Li YQ; Han XY; Lan C; Tang J; Tan Y; Mo CY; Yang WZ; Han JL; Huang XX
    Clin Res Hepatol Gastroenterol; 2023 May; 47(5):102125. PubMed ID: 37062356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg).
    Nyssen OP; Perez-Aisa A; Tepes B; Castro-Fernandez M; Kupcinskas J; Jonaitis L; Bujanda L; Lucendo A; Jurecic NB; Perez-Lasala J; Shvets O; Fadeenko G; Huguet JM; Kikec Z; Bordin D; Voynovan I; Leja M; Machado JC; Areia M; Fernandez-Salazar L; Rodrigo L; Alekseenko S; Barrio J; Ortuño J; Perona M; Vologzhanina L; Romero PM; Zaytsev O; Rokkas T; Georgopoulos S; Pellicano R; Buzas GM; Modolell I; Gomez Rodriguez BJ; Simsek I; Simsek C; Lafuente MR; Ilchishina T; Camarero JG; Dominguez-Cajal M; Ntouli V; Dekhnich NN; Phull P; Nuñez O; Lerang F; Venerito M; Heluwaert F; Tonkic A; Caldas M; Puig I; Megraud F; O'Morain C; Gisbert JP;
    Am J Gastroenterol; 2021 Jun; 116(6):1220-1229. PubMed ID: 33840725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ten-day Quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for Helicobacter pylori infection after failure of sequential therapy.
    Hsu PI; Chen WC; Tsay FW; Shih CA; Kao SS; Wang HM; Yu HC; Lai KH; Tseng HH; Peng NJ; Chen A; Kuo CH; Wu DC;
    Helicobacter; 2014 Feb; 19(1):74-9. PubMed ID: 24033865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antofloxacin-based bismuth quadruple therapy is safe and effective in Helicobacter pylori eradication: A prospective, open-label, randomized trial.
    He XJ; Zeng XP; Jiang CS; Liu G; Li DZ; Wang W
    Arab J Gastroenterol; 2021 Mar; 22(1):47-51. PubMed ID: 33551347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of 10 and 14 days of antofloxacin-based versus 14 days of clarithromycin-based bismuth quadruple therapy for Helicobacter pylori eradication: A randomized trial.
    He XJ; Wang XL; Huang XY; Li DZ; Liu G; Wang W; Li DL
    Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102052. PubMed ID: 36400418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors of rescue bismuth quadruple therapy failure for Helicobacter pylori eradication.
    Lee JW; Kim N; Nam RH; Lee SM; Soo In C; Kim JM; Lee DH
    J Gastroenterol Hepatol; 2019 Apr; 34(4):666-672. PubMed ID: 30726563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.